Quercis Pharma is a biopharmaceutical company that brings innovative and safe medicine to patients with orphan diseases. It is advancing a development pipeline of late-stage clinical studies that focus on the prevention of VTE in cancer patients. In addition, Quercis targets other diseases associated with thrombotic events, such as sickle cell disease (SCD), Ebola, and COVID-19. The Company’s lead drug candidate acts as an antithrombotic with a significantly lower risk of adverse events than existing treatments.
The company was founded in 2019 and is based in Zug, Switzerland.